热门资讯> 正文
辉瑞因Metsera交易而提前终止HSR
2025-11-01 04:17
- Pfizer (PFE) said it was granted HSR early termination by the Federal Trade Commission for its planned purchase of Metsera (MTSR).
- The termination of the waiting period satisfies the regulatory review requirements, which was set to expire on Nov. 7, Pfizer said in a statement on Friday.
- The regulatory approval comes a day after Novo Nordisk (NVO) outbid Pfizer (PFE) for Metsera (MTSR). Pfizer has until Tuesday to match the offer, which Metsera (MTSR) deemed as "superior."
- Pfizer (PFE) on Thursday called the Metsera (MTSR) bid " an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk.
More on Metsera, Pfizer
- Metsera Becomes The Prize In Obesity's Biggest Bidding War
- Why Pfizer's Headwinds May Already Be In The Price
- Did Pfizer Overpay For Yet Another Acquisition?
- Pfizer considers suing Metsera, Novo over topping bid - report
- Metsera says Novo Nordisk’s $9B buyout offer “superior”; Pfizer calls bid “illusory”
推荐文章
美股机会日报 | 停摆已达36天！美政府停摆时间创史上最长纪录；就业风向标“小非农”今晚公布
11月财报预告 | 明星科网股财报在即！英伟达、腾讯控股、京东等巨头将发财报，谁将带来惊喜？
遭马斯克粉丝威胁“销户”，嘉信理财决定投票支持其薪酬方案
Palantir CEO炮轰“大空头”：做空我们和英伟达“简直疯了”！
Tempus AI(TEM.US)Q3营收同比增84.7%超市场预期 净亏损8000万美元同比扩大5.5%
马斯克称特斯拉AI5芯片2027年才能量产，AI6要到2028年
AMD第三季度营收92.46亿美元 净利润同比增长61%
11月5日外盘头条：美国政府停摆追平纪录 IBM裁员数千人 比特币跌破10万美元 苹果拟推出低价笔记本电脑
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
